This marks the second supply collaboration related to its treatment of chronic fatigue in MS patients.
MultiCell Technologies entered into an agreement with Merck KGaA & Co. for the formulation and supply of one of the active components in its drug related to multiple sclerosis (MS). MCT-125 is currently in Phase IIb trials for the treatment of chronic fatigue in MS patients.
In a 138-patient, multicenter, double-blind, placebo-controlled study, MCT-125 demonstrated efficacy in significantly reducing the levels of fatigue in all three types of MS patients enrolled in the study, according to MultiCell.
“This contract is another key component required for us to commence planned Phase IIb human clinical trials,” notes Stephen Chang, president and CEO of MultiCell Technologies. “We are building a solid foundation for the future development of this much needed therapeutic, and each new agreement brings this plan closer to reality.”
